CJC-1295
Long-acting GHRH analog studied in GH signaling research.
Evidence Level
Low
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Long-acting GHRH analog studied in GH signaling research.
/ 02
Mechanism of Action
Studied for sustained GHRH receptor activation.
/ 03
Research Applications
GH/IGF-1 amplitude research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
CJC-1295 is a long-acting GHRH analog. Research describes prolonged stimulation of GH and IGF-1 secretion, with some forms designed to preserve pulsatility of GH release.
/ 08
Pathway Role
Sits within the GH/IGF-1 axis at the GHRH receptor signaling layer, with extended pharmacokinetic profile.
/ 09
Biological Targets
/ 10
Research Applications
- GH axis pharmacodynamic studies
- Endocrine response research
/ 11
Evidence Summary
Limited modern clinical outcome data. Most evidence is pharmacodynamic in nature.
Evidence Level Rationale
Rated low-to-moderate due to limited controlled clinical outcome trials.
/ 12
Research Observation Timeline
Early Signal Window
Hormonal marker shifts within hours to days
Primary Study Window
Days to weeks for pharmacodynamic studies
Endpoint Type
Pharmacodynamic hormone endpoints
Evidence Strength
Low to moderate (pharmacodynamic only)
/ 13
Safety & Unknowns
Long-term safety and outcome data are not well-characterized in controlled studies.
/ 14
Research Limitations
Outcome timing for body composition or performance endpoints is not established.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Low
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
Ipamorelin
Selective GH secretagogue studied for ghrelin receptor signaling.
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.